Vertaling van "during the first " (Nederlands → Frans) :

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).

Credit agencies maintained their ratings of Novartis debt during the first quarter of 2010.
Au premier trimestre 2010, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

The vast majority came from recognition of sales for deliveries made during the first quarter as part of supply contracts reached in 2009.
La majorité de cette hausse provient de la comptabilisation des ventes pour des livraisons effectuées au premier trimestre 2010 dans le cadre de contrats passés en 2009.

Credit agencies maintained their ratings of Novartis during the first half of 2010.
Au deuxième trimestre 2010, les agences de notation ont maintenu leurs notes pour Novartis.

Credit agencies maintained their ratings of Novartis debt during the first half of 2009.
Au premier semestre 2009, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.
●● Efficacy: the active ingredient is as such subject to an authorisation or prequalification by the WHO or a positive opinion from the EMEA During this first year of activity, The Production & Distribution department issued 149 EDs.

In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information
In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information

With a view to the further optimisation of the working processes, structure and deployment of available resources, the FAMPS’s structure was redesigned during the first main phase of the transition.
With a view to the further optimisation of the working processes, structure and deployment of available resources, the FAMPS’s structure was redesigned during the first main phase of the transition.

During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.
During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.

Ilaris, a fully human monoclonal antibody that blocks action of the inflammatory protein interleukin-1 beta, has been launched after receiving first approvals during 2009 in the US, Europe and some other markets for treatment of cryopyrin-associated periodic syndrome (CAPS), a group of rare lifelong auto-inflammatory disorders.
Ilaris, un anticorps monoclonal entièrement humain qui bloque l’action de l’interleukine-1 bêta (IL- 1β), une protéine inflammatoire, a été lancé après avoir obtenu ses premières autorisations en 2009 aux Etats-Unis, en Europe et dans quelques autres marchés pour le traitement du syndrome périodique associé à la cryopirine (CAPS), un groupe de maladies rares auto-inflammatoires tout au long de la vie.